Versant

VC firm · San Francisco, CA

Verified active in the last 12 monthsSEC-registered adviser

Venture firm based in San Francisco, CA. Most recent fund on file: Versant Vantage III, L.P. ($299M offering), filed Apr 2023. 1 deal vehicle (SPVs) filed with the SEC since May 2024. Partners sit on the boards of 8 startups that raised recently.

“Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.” (from the firm’s website)

Stages: Seed to Growth
Typical check (est.): $2.98M–$8.95M
Latest fund: $299M · Apr 2023
Last verified activity: Mar 2026

Focus

Biotech & Pharma

Recent portfolio activity

Nexo Therapeutics
Board seat · CO
Mar 2026
Pep2Tango Therapeutics
Board seat · MD
Nov 2024
858 Therapeutics
Board seat · CA
Jul 2024
Lycia Therapeutics
Board seat · CA
May 2024
Firefly Bio
Board seat · CA
Mar 2024
Jnana Therapeutics
Board seat · MA
Jan 2024
Lenz Therapeutics
Board seat · CA
Mar 2023
Santa Ana Bio
Board seat · CA
Feb 2023

Funds and vehicles on SEC file

Versant Venture Capital SPV I (SAB), L.P.
Deal vehicle · $5M offering
May 2024
Versant Vantage III, L.P.
Fund · $299M offering
Apr 2023
Versant Voyageurs III, L.P.
Fund · $300M offering
Apr 2023
Versant Venture Capital IX, L.P.
Fund · $600M offering
Apr 2023

Sources

SEC Form D: Versant Venture Capital SPV I (SAB), L.P.May 9, 2024
SEC Form D: Versant Vantage III, L.P.Apr 7, 2023
SEC Form D: Versant Voyageurs III, L.P.Apr 7, 2023
SEC Form D: Versant Venture Capital IX, L.P.Apr 7, 2023
SEC adviser record: Versant Venture Management, LLCMar 30, 2026
Firm websiteOct 12, 2026

Profile last verified Oct 12, 2026. Is this you? Correct or remove this profile.